The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.

Planned CABG or planned PCI or planned major non-cardiac surgery within study period

No measurable Lp-PLA2 activity in plasma (<10 nmol/min/mL) at screening

Change in a lipid-lowering medication, regimen or dosage during the 4 week prior to randomization

Poorly controlled dyslipidemia (LDL-c >=160 mg/dL) at screening

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00734032